A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This Phase III single-arm study is to evaluate the efficacy and safety of IMGN853 in Chinese
adult patients with platinum-resistant high-grade epithelial ovarian, primary peritoneal, or
fallopian tube cancers (hereafter referred to as PROC) with high FRĪ± expression.